


## NSCLC: Localized Disease/Resectable

Revised: August 21, 2017



**VICC THO 1718**  
 Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 816)


**ECOG THO A081105**  
 Randomized Double Blind Placebo Controlled Study of ERLOTINIB or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)


**ECOG THO E4512**  
 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

**ECOG THO EA5142**  
 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non- Small Cell Lung Cancers

Check the multi-disease flowchart for additional clinical trials.

**KEY**

 Accrual on hold

 Open